Shots:

• The Gate Foundation has granted $13M to fund development program addressing the lack of global family planning options. The development of once-monthly oral contraceptive will provide women with a discreet- non-invasive option to support their family planning
• Additionally- the Gates Foundation awarded a grant to Lyndra to develop long-acting malaria therapy and will provide funds for P-II clinical study- expansion of its P-I pipeline and manufacturing scale-up
• Lyndra’s once-monthly oral combination therapy delivers sustained- the steady-state release of estrogen and progestin improving medication adherence and health outcomes while reducing the burdens on individuals and their caregivers

Click here to­ read full press release/ article | Ref: Lyndra Therapeutics | Image: The Pharma Letter